---
reference_id: "PMID:34798988"
title: Lynch Syndrome-Associated Cancers Beyond Colorectal Cancer.
authors:
- Biller LH
- Creedon SA
- Klehm M
- Yurgelun MB
journal: Gastrointest Endosc Clin N Am
year: '2022'
doi: 10.1016/j.giec.2021.08.002
content_type: abstract_only
---

# Lynch Syndrome-Associated Cancers Beyond Colorectal Cancer.
**Authors:** Biller LH, Creedon SA, Klehm M, Yurgelun MB
**Journal:** Gastrointest Endosc Clin N Am (2022)
**DOI:** [10.1016/j.giec.2021.08.002](https://doi.org/10.1016/j.giec.2021.08.002)

## Content

1. Gastrointest Endosc Clin N Am. 2022 Jan;32(1):75-93. doi: 
10.1016/j.giec.2021.08.002.

Lynch Syndrome-Associated Cancers Beyond Colorectal Cancer.

Biller LH(1), Creedon SA(2), Klehm M(2), Yurgelun MB(3).

Author information:
(1)Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA; 
Harvard Medical School, Boston, MA 02215, USA; Brigham & Women's Hospital, 
Boston, MA 02215, USA.
(2)Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.
(3)Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA; 
Harvard Medical School, Boston, MA 02215, USA; Brigham & Women's Hospital, 
Boston, MA 02215, USA. Electronic address: matthew_yurgelun@dfci.harvard.edu.

Lynch syndrome (LS) is a common form of inherited cancer susceptibility, which 
predisposes to colorectal cancer (CRC) along with a wide array of other 
extracolonic malignancies, including other gastrointestinal cancers, cancers of 
the gynecologic and genitourinary tracts, and other organ sites. Recent data 
have provided novel insights into patient-specific factors that can help 
clinicians understand an individual LS carrier's risk of extracolonic cancers, 
including sex, specific LS gene, age, family history of cancer, and other 
factors. This summary seeks to provide an update on extracolonic cancer risks in 
LS and provide recommendations for surveillance and risk reduction.

Copyright Â© 2021 Elsevier Inc. All rights reserved.

DOI: 10.1016/j.giec.2021.08.002
PMID: 34798988 [Indexed for MEDLINE]

Conflict of interest statement: Disclosure Dr M.B. Yurgelun reports 
consulting/scientific advisory board fees and research funding from Janssen 
Pharmaceuticals as well as payments for peer review services from UpToDate. The 
authors have nothing to disclose.